Pediatrix Medical Group Balance Sheet Health
Finanzielle Gesundheit Kriterienprüfungen 2/6
Pediatrix Medical Group hat ein Gesamteigenkapital von $856.2M und eine Gesamtverschuldung von $709.8M, wodurch sich der Verschuldungsgrad auf 82.9% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen $2.2B bzw. $1.3B. Pediatrix Medical Group Das EBIT des Unternehmens beträgt $152.2M, so dass der Zinsdeckungsgrad 4.2 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von $115.5M.
Wichtige Informationen
82.9%
Verhältnis von Schulden zu Eigenkapital
US$709.76m
Verschuldung
| Zinsdeckungsgrad | 4.2x |
| Bargeld | US$115.47m |
| Eigenkapital | US$856.20m |
| Gesamtverbindlichkeiten | US$1.31b |
| Gesamtvermögen | US$2.17b |
Jüngste Berichte zur Finanzlage
Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?
Jun 19
Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?
Nov 14Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?
Aug 09Pediatrix Medical Group (NYSE:MD) Has A Somewhat Strained Balance Sheet
Apr 26Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?
Jan 12Here's Why Pediatrix Medical Group (NYSE:MD) Can Manage Its Debt Responsibly
Sep 13Recent updates
Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?
Jun 19Pediatrix Medical Group (NYSE:MD) Has Some Way To Go To Become A Multi-Bagger
May 10Pediatrix Medical Group, Inc.'s (NYSE:MD) Price Is Right But Growth Is Lacking
Mar 29Pediatrix Medical Group, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 100% Above Its Share Price
Jan 10Pediatrix Medical Group, Inc.'s (NYSE:MD) Earnings Are Not Doing Enough For Some Investors
Dec 25Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?
Nov 14Is It Time To Consider Buying Pediatrix Medical Group, Inc. (NYSE:MD)?
Oct 13Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?
Aug 09Pediatrix: Unable To Deploy Capital Tied Up In Cash Conversion Cycle, Reiterate Hold
Aug 08At US$14.21, Is Pediatrix Medical Group, Inc. (NYSE:MD) Worth Looking At Closely?
Jul 03The Returns At Pediatrix Medical Group (NYSE:MD) Aren't Growing
Jun 08Pediatrix Medical Group (NYSE:MD) Has A Somewhat Strained Balance Sheet
Apr 26Is Now An Opportune Moment To Examine Pediatrix Medical Group, Inc. (NYSE:MD)?
Feb 20Pediatrix Medical Group Q4 2022 Earnings Preview
Feb 16Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?
Jan 12Pediatrix: RCM Overhang Now Too Heavy, Revise To Hold
Dec 22Return Trends At Pediatrix Medical Group (NYSE:MD) Aren't Appealing
Dec 20Pediatrix appoints James Swift as chief executive officer
Dec 15Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching
Nov 05Pediatrix Medical Group GAAP EPS of $0.37 misses by $0.11, revenue of $489.92M misses by $21.54M
Nov 03Pediatrix: These 5 Graphs Suggest It's A Buy
Sep 29Here's Why Pediatrix Medical Group (NYSE:MD) Can Manage Its Debt Responsibly
Sep 13Here's What To Make Of Pediatrix Medical Group's (NYSE:MD) Decelerating Rates Of Return
Aug 29Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching
Jul 27Pediatrix: Seeking 46% Return Objective As Speculative Buy
Jul 14MEDNAX, Inc. (NYSE:MD) Shares Could Be 47% Below Their Intrinsic Value Estimate
Jun 24MEDNAX (NYSE:MD) Has A Pretty Healthy Balance Sheet
May 25Return Trends At MEDNAX (NYSE:MD) Aren't Appealing
Apr 20MEDNAX, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 96% Above Its Share Price
Mar 08MEDNAX (NYSE:MD) Seems To Use Debt Quite Sensibly
Feb 15Here's What's Concerning About MEDNAX's (NYSE:MD) Returns On Capital
Jan 19Is MEDNAX, Inc. (NYSE:MD) Trading At A 40% Discount?
Nov 17These 4 Measures Indicate That MEDNAX (NYSE:MD) Is Using Debt Reasonably Well
Oct 23Here's What's Concerning About MEDNAX's (NYSE:MD) Returns On Capital
Oct 08Is MEDNAX (NYSE:MD) A Risky Investment?
Jul 19MEDNAX (NYSE:MD) Could Be Struggling To Allocate Capital
Jun 27Statutory Profit Doesn't Reflect How Good MEDNAX's (NYSE:MD) Earnings Are
May 15Mednax Q1 2021 Earnings Preview
May 06Analyse der Finanzlage
Kurzfristige Verbindlichkeiten: MDDie kurzfristigen Aktiva des Unternehmens ($426.5M) übersteigen seine kurzfristigen Passiva ($247.3M).
Langfristige Verbindlichkeiten: MDDie kurzfristigen Vermögenswerte des Unternehmens ($426.5M) decken seine langfristigen Verbindlichkeiten ($1.1B) nicht.
Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital
Verschuldungsgrad: MDDie Nettoverschuldung im Verhältnis zum Eigenkapital (69.4%) wird als hoch angesehen.
Schulden abbauen: MDDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 76.2% auf 82.9% gestiegen.
Schuldendeckung: MDDie Schulden des Unternehmens sind nicht ausreichend durch den operativen Cashflow (15.9%) gedeckt.
Zinsdeckung: MDDie Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (4.2x Coverage) gut gedeckt.